Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	0.01	0.02	0.01	0	0
Cash & Short-Term Investments	0.01	0.02	0.01	0	0
Cash Growth	-42.67%	109.86%	147.04%	80.36%	-96.64%
Other Receivables	0.01	0	0	0	0
Receivables	0.01	0	0	0	0
Prepaid Expenses	8.33	-	0.01	0.01	-
Other Current Assets	0	0	-	-	-
Total Current Assets	8.35	0.03	0.02	0.02	0.01
Property, Plant & Equipment	0.06	0.02	0.04	0.06	0
Long-Term Deferred Charges	0.29	0.03	-	-	-
Other Long-Term Assets	10.93	0	0	0	0
Total Assets	19.63	0.07	0.06	0.08	0.01
Accounts Payable	1.25	1.21	0.97	0.94	1
Accrued Expenses	2.35	1.53	1.21	0.94	1.31
Short-Term Debt	1.56	0.87	0.51	0.98	0.68
Current Portion of Leases	0.02	0.02	0.02	0.02	-
Other Current Liabilities	0.4	0.16	0.45	0.18	0.09
Total Current Liabilities	5.58	3.79	3.16	3.06	3.08
Long-Term Debt	0.11	0.06	-	-	-
Long-Term Leases	0.04	-	0.02	0.04	-
Total Liabilities	5.73	3.85	3.18	3.11	3.08
Common Stock	0.01	0	0.01	0	0.01
Additional Paid-In Capital	138.24	61.7	60.31	57.36	54.07
Retained Earnings	-125.62	-66.7	-64.68	-61.56	-58.2
Treasury Stock	-0.05	-0.05	-0.05	-0.05	-0.05
Comprehensive Income & Other	1.32	1.27	1.29	1.21	1.09
Total Common Equity	13.91	-3.78	-3.12	-3.03	-3.07
Shareholders' Equity	13.91	-3.78	-3.12	-3.02	-3.07
Total Liabilities & Equity	19.63	0.07	0.06	0.08	0.01
Total Debt	1.73	0.95	0.55	1.04	0.68
Net Cash (Debt)	-1.71	-0.93	-0.54	-1.04	-0.68
Net Cash Per Share	-0.43	-	-	-	-
Filing Date Shares Outstanding	12.81	0.01	-	-	-
Total Common Shares Outstanding	11.61	-	-	-	-
Working Capital	2.77	-3.77	-3.14	-3.05	-3.07
Book Value Per Share	1.20	-	-	-	-
Tangible Book Value	13.91	-3.78	-3.12	-3.03	-3.07
Tangible Book Value Per Share	1.20	-	-	-	-
Machinery	-	-	0.03	0.03	0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.